-
公开(公告)号：US11065216B2
公开(公告)日：2021-07-20
申请号：US16461597
申请日：2017-11-16
发明人： Kee-Hong Kim , Yuyan Zhu
IPC分类号： A61K31/18 , A61P3/04 , A61K31/167 , C12N15/113
摘要： A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.
-
公开(公告)号：US11065210B2
公开(公告)日：2021-07-20
申请号：US16582118
申请日：2019-09-25
申请人： 10XBIO, LLC
摘要： Described herein, inter alia, are compositions, formulations, methods, and systems for reducing regional fat deposits and treating fat-related conditions.
-
公开(公告)号：US11059894B2
公开(公告)日：2021-07-13
申请号：US16696411
申请日：2019-11-26
申请人： Acceleron Pharma Inc. , Adimab, LLC
发明人： John Knopf , Jonathan Belk , Nathan J. Sharkey , Ravindra Kumar , Asya Grinberg , Dianne Sako , Roselyne Castonguay , Yossi Dagon
摘要： This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
-
公开(公告)号：US20210206853A1
公开(公告)日：2021-07-08
申请号：US17056663
申请日：2019-05-17
发明人： Horst Lindhofer , Ursula Jacob
IPC分类号： C07K16/28 , A61K39/395 , A61P43/00 , A61P11/14 , A61P3/10 , A61P29/00 , A61P25/02 , A61P15/00 , A61P37/04 , A61P25/28 , A61P19/02 , A61P27/02 , A61P15/02 , A61P3/04 , A61P31/14 , C12N5/0781 , C12N5/078 , A61K35/17 , A61K35/14
摘要： The present invention discloses an isolated trifunctional bispecific antibody for use in a method of treating a patient suffering from a disease and/or a disorder associated with reactivation of Epstein-Barr vims (EBV) in at least B cells and potentially also other susceptible cells such as susceptible epithelial cells, comprising: providing an autologous cell preparation of enriched B cells of said patient; incubating said enriched B cells with the trifunctional bispecific antibody for a time-period sufficient to establish a physical interaction between said trifunctional bispecific antibody and said enriched B cells to obtain an incubation mixture; transferring said incubation mixture obtained after incubation into the same patient, wherein said trifunctional bispecific antibody comprises: (a) a first binding arm which binds to a B cell via a B cell surface antigen; (b) a second binding arm which binds to a T cell via a T cell surface antigen; (c) an Fc-portion which binds to an Fc receptor-positive cell. The present invention also discloses a pharmaceutical composition comprising the said isolated trifunctional bispecific antibody for use in the treatment of a patient suffering from a disease and/or a disorder associated with reactivation of EBV in B cells, and an ex-vivo method for preparing the said pharmaceutical composition.
-
公开(公告)号：US20210196747A1
公开(公告)日：2021-07-01
申请号：US17057348
申请日：2019-05-24
发明人： Hiroaki MASUZAKI , Hideki NAKAMURA , Toshitake HIRAI , Kaoru HARA , Takashi KANDA , Satomi YAMASAKI , Tadashi KOBAYASHI , Koichiro NISHIOKA
摘要： Provided is a metabolism improving agent that contains, for example, an alkalizing agent such as an acidosis improving agent or a urinary alkalizing agent as an active ingredient, and has actions such as improvement of insulin resistance, improvement of pituitary and adrenal functions, and reduction of visceral fat accumulation.
-
公开(公告)号：US11045514B2
公开(公告)日：2021-06-29
申请号：US16558246
申请日：2019-09-02
申请人： Vidya Herbs, Inc.
IPC分类号： A61K36/53 , A61K31/19 , A61K31/045 , A61K9/68 , A61P3/04 , A61K9/20 , A61K9/48 , A23L33/00 , A23L33/105 , A61K9/00
摘要： A method of modulating body weight using a composition of rosemary extract having a pre-determined amount of ursolic acid.
-
公开(公告)号：US11045478B2
公开(公告)日：2021-06-29
申请号：US16680093
申请日：2019-11-11
申请人： Essentialis, Inc.
发明人： Neil M. Cowen , Khaled A. Yamout
IPC分类号： A61K31/137 , A61K31/365 , A61K31/42 , A61K31/357 , A61K31/4355 , A61K31/549 , A61P3/10 , A61P3/04 , A61K31/54 , C07D285/24 , C07C209/68 , C07C213/08 , A61K9/20 , A61K45/06 , A61K38/27
摘要： Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
-
公开(公告)号：US11045439B2
公开(公告)日：2021-06-29
申请号：US16860232
申请日：2020-04-28
发明人： Umut Ozcan , Joseph Majzoub , Ralph Mazitschek
IPC分类号： A61K31/198 , A61K31/192 , A61K31/194 , A61K31/195 , A61K38/22 , A61P3/04 , A61K31/19 , A61K45/06
摘要： Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
-
公开(公告)号：US20210188970A1
公开(公告)日：2021-06-24
申请号：US17124481
申请日：2020-12-16
发明人： Zhiqiang An , Ningyan Zhang , Philipp E. Scherer , Shangang Zhao
摘要： Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.
-
公开(公告)号：US20210188937A1
公开(公告)日：2021-06-24
申请号：US17187098
申请日：2021-02-26
发明人： Euh Lim OH , Jong Suk LEE , Young Jin PARK , Chang Ki LIM , Sung Youb JUNG , Se Chang KWON
IPC分类号： C07K14/605 , A61K38/26 , A61P3/04 , A61P3/10 , A61K39/395 , C07K14/47 , C07K16/28
摘要： A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
-
-
-
-
-
-
-
-
-
搜索结果
6632 条记录 (耗时 0.06 秒)
